Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of allopurinol treatment for autistic disorders and epilepsy in adenylosuccinate lyase deficiency
2017-002155-28Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allopurinol in Adenylosuccinate lyase deficiency (ADSL), Autism Spectrum Disorder (ASD) and epilepsy, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: 12-month adaptive and cognitive functioning. Started Jun 2018; status: completed.
02
Drugs
allopurinol
03
Conditions
Adenylosuccinate lyase deficiency (ADSL)Autism Spectrum Disorder (ASD)epilepsy
Beyond the preview
Go deeper on 2017-002155-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002155-28.